product summary
Loading...
company name :
R&D Systems
product type :
other
product name :
Cultrex Basement Membrane Extract, Type 3, Pathclear
catalog :
3632-010-02
quantity :
10 mL (2 x 5 mL)
price :
378 USD
more info or order :
R&D Systems product webpage
citations: 19
Reference
Zheng W, Marini W, Murakami K, Sotov V, Butler M, Gorrini C, et al. Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy. Nat Commun. 2024;15:8514 pubmed publisher
Lupo K, Panjwani M, Shahid S, Sottile R, Lawry C, Kolk G, et al. Engineered NKG2C + NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome. bioRxiv. 2024;: pubmed publisher
Calhoon D, Sang L, Bezwada D, Kim N, Basu A, Hsu S, et al. Glycosaminoglycan-mediated lipoprotein uptake protects cancer cells from ferroptosis. bioRxiv. 2024;: pubmed publisher
Soumoy L, Genbauffe A, Mouchart L, Sperone A, Trelcat A, Mukeba Harchies L, et al. ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell Int. 2024;24:8 pubmed publisher
Chougoni K, Park H, Damle P, Mason T, Cheng B, Dcona M, et al. Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma. Oncogenesis. 2023;12:53 pubmed publisher
Vinod N, Hwang D, Fussell S, Owens T, Tofade O, Copling S, et al. Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC. bioRxiv. 2023;: pubmed publisher
Cui W, Huang Z, Jin S, Johnson J, Lau K, Hostetter G, et al. Deficiency of the Polycomb protein RYBP and TET methylcytosine oxidases promotes extensive CpG island hypermethylation and malignant transformation. Cancer Res. 2023;: pubmed publisher
Delbart W, Marin G, Stamatopoulos B, De Wind R, Sirtaine N, Demetter P, et al. Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Cancers (Basel). 2023;15: pubmed publisher
Yi Q, Liu W, Seo J, Su J, Alaoui Jamali M, Luo J, et al. Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2023;22:570-582 pubmed publisher
Zhong X, Luan J, Yu A, Lee Hassett A, Miao Y, Yang L. SFyNCS detects oncogenic fusions involving non-coding sequences in cancer. bioRxiv. 2023;: pubmed publisher
Londo xf1 o Berrio M, Castro C, Ca xf1 as A, Ortiz I, Osorio M. Advances in Tumor Organoids for the Evaluation of Drugs: A Bibliographic Review. Pharmaceutics. 2022;14: pubmed publisher
Kim K, Jeong B, Lee Y, Son H, Ryu J, Park S, et al. Three-Dimensional Kidney-on-a-Chip Assessment of Contrast-Induced Kidney Injury: Osmolality and Viscosity. Micromachines (Basel). 2022;13: pubmed publisher
Decker S, Arango Ospina M, Rehder F, Moghaddam A, Simon R, Merle C, et al. In vitro and in ovo impact of the ionic dissolution products of boron-doped bioactive silicate glasses on cell viability, osteogenesis and angiogenesis. Sci Rep. 2022;12:8510 pubmed publisher
Palazzolo S, Caligiuri I, Sfriso A, Mauceri M, Rotondo R, Campagnol D, et al. Early Warnings by Liver Organoids on Short- and Long-Chain PFAS Toxicity. Toxics. 2022;10: pubmed publisher
Yin L, Zeng Y, Zeng R, Chen Y, Wang T, Rodabaugh K, et al. Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer. Oncogene. 2021;40:6772-6785 pubmed publisher
Yamazaki C, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12:3528 pubmed publisher
Yang R, Sun L, Li C, Wang Y, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12:832 pubmed publisher
Cheng J, Klei L, Hubel N, Zhang M, Schairer R, Maurer L, et al. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein. J Clin Invest. 2020;130:1036-1051 pubmed publisher
Doçi C, Mikelis C, Lionakis M, Molinolo A, Gutkind J. Genetic Identification of SEMA3F as an Antilymphangiogenic Metastasis Suppressor Gene in Head and Neck Squamous Carcinoma. Cancer Res. 2015;75:2937-48 pubmed publisher
product information
brand :
R&D Systems
master code :
3632-010-02
SKU :
3632-010-02
product name :
Cultrex Basement Membrane Extract, Type 3, Pathclear
unit size :
10 mL (2 x 5 mL)
target :
Basement Membrane Extracts
category :
Cell Culture Products
buffer :
12 - 18 mg/ml.
dilution :
Bioactivity
details of functionality :
Functional assay: Tumor Growth Assay - BME Type 3 supports proliferation and growth of breast cancer cells (MCF7) embedded in the matrix for minimum of 8 days. Gelling assay: BME gels in less than 30 minutes at 37░C, and maintains the gelled form in culture medium for a minimum of 14 days at 37░C.
endotoxin note :
<8.0 EU per 1 ╡g of the protein by the LAL method.
top caption :
Cultrex Basement Membrane Extract, Type 3
applications :
Bioactivity
extended description :
Basement Membrane Extract for xenograft and in vivo tumor modeling
USD :
378 USD
product details :
Basement Membrane Extract for xenograft and in vivo tumor modeling
storage :
Product is stable for a minimum of 3 months from date of shipment when stored at -20 ░C in a manual defrost freezer. For optimal stability, store at -80 ░C. Avoid freeze-thaw cycles. Storage Buffer: RPMI1640 medium without phenol red. Sterility Testing: PathClear« - Negative by PCR test for mycoplasma; 17 bacterial and virus strains typically included in mouse antibody production (MAP) testing, plus 13 additional murine infectious agents including LDEV, for a total of 31 organisms and viruses. No bacterial or fungal growth detected after incubation at 37 ░C for 14 days following USP sterility testing guidelines.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.